不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
复发/难治性结外自然杀伤/T 细胞淋巴瘤的机制与干预
英文原题：Mechanisms and interventions in relapsed/refractory extranodal natural killer/T-cell lymphoma.
查看英文原题
Mechanisms and interventions in relapsed/refractory extranodal natural killer/T-cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
结外自然杀伤/T细胞淋巴瘤（ENKTL）是一种与Epstein-Barr病毒相关的侵袭性非霍奇金淋巴瘤，通常累及结外部位。传统的CHOP方案由于耐药已不再是标准治疗，而基于门冬酰胺酶的疗法已成为主要治疗手段。然而，耐药和肿瘤侵袭导致40-50%的患者复发，其中20%进展为复发/难治性ENKTL，中位生存期<12个月。ENKTL的管理仍然具有挑战性，存在未满足的临床需求。然而，尽管复发/难治性ENKTL的预后较差，但随着对该疾病认识的深入，新的治疗策略正在不断发展。本综述探讨了导致治疗耐药的因素、潜在的耐药机制以及克服ENKTL耐药的潜在策略。
展开英文摘要原文
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin's lymphoma associated with Epstein-Barr virus and typically involves extranodal sites. The traditional CHOP regimen is no longer standard owing to drug resistance, whereas asparaginase-based therapies have become the mainstay of treatment.
However, resistance and tumor invasion lead to relapses in 40-50% of patients, with 20% progressing to relapsed/refractory ENKTL, resulting in a median survival of <12 months. Management of ENKTL remains challenging, with an unmet clinical need.
However, although the prognosis for relapsed/refractory ENKTL is poor, the development of new treatment strategies is progressing with a better understanding of the disease. This review examines factors contributing to treatment resistance, underlying resistance mechanisms and potential strategies to overcome ENKTL resistance.
论文信息
- 作者
- Lu Q、You T、Cheng Q、Chen ZS、Huang H
- 第一作者单位
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Department of Hematology, Foresea Life Insurance Guangzhou General Hospital, Guangzhou, China.China
- 通讯作者单位
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. Electronic address: huanghaiwen@suda.edu.cn.China
- 文献类型
- 综述
- 期刊
- Drug discovery today2025 Dec
- 原文标识
- PubMed 41265515 · DOI 10.1016/j.drudis.2025.104549